The harmonious journey of Clinical Outcomes Solutions and FingerPost reaches a triumphant milestone, as they celebrate five years of transformative collaboration.

COS, a global clinical research consulting group providing 360° support and services across all facets of clinical outcomes research, melds its brilliance with FingerPost, a visionary consultancy specializing in payer insights and Health Technology Assessment (HTA) intelligence.

From the inception in 2013, COS's resounding excellence reverberates in its innovative pursuit of capturing and amplifying the patient voice. Through qualitative and quantitative research, COS delivers the beacon of actionable evidence in clinical drug development, with Clinical Outcomes Assessments (COAs) as its compass.

Enter FingerPost, a luminary in market access and pricing strategy. Armed with the expertise to shape pharmaceutical launch success, FingerPost joins forces with COS, resulting in a force of industry brilliance.

This enduring partnership orchestrates COS projects with unparalleled precision, offering bespoke insights into the realm of Clinical Outcomes Assessment data. Clients reap the rewards by embracing a comprehensive perspective, not only aligning with regulatory prerequisites but navigating the intricate payer and HTA landscape. Informed decisions are the cornerstone, fostering market access prowess and cultivating a robust foundation for growth. All the while, clients enjoy the seamlessness of a singular point of contact.

The tapestry of their collaboration is adorned with over 30 completed endeavors since 2016. This dynamic duo of subject matter experts, specializing in COA strategy, pricing dynamics, market access acumen, and reimbursement nuances, unites under the COS and FingerPost banner. The outcome is a masterpiece of flexibility, efficiency, and expertise - a true synergy that thrives on a meticulously crafted methodology.

Stacie Hudgens, the visionary Chief Executive Officer at COS, illuminates;

“The partnership between COS and Fingerpost is an ode to scientific synergy, dedicated to painting the COA Competitive Landscape for our Sponsor clients in the anti-cancer therapy realm. Our shared commitment to unraveling the patient's voice in outcomes and clinical research forms the essence of evidence synthesis, charting the course for new drug development.”

Stacie Hudgens
CEO, Clinical Outcomes Solutions

Catherine Bacon, the astute Managing Director of FingerPost, reflects:

“FingerPost enriches our tapestry, bestowing our Sponsors with a heightened realm of expertise. The resulting depth of insight in COA landscape analysis fuels avant-garde COA strategies, unraveling maximal value to our invaluable stakeholders. In COS and FingerPost, the global reach finds its echo, resonating in our commitment to pioneering science with the patient's pulse at its heart.”

Catherine Bacon
Managing Director, FingerPost

Tara Symonds, the esteemed Chief Science Officer at COS, elevates the partnership's essence:

“FingerPost enriches our tapestry, bestowing our Sponsors with a heightened realm of expertise. The resulting depth of insight in COA landscape analysis fuels avant-garde COA strategies, unraveling maximal value to our invaluable stakeholders. In COS and FingerPost, the global reach finds its echo, resonating in our commitment to pioneering science with the patient's pulse at its heart.”

Tara Symonds
CSO, Clinical Outcomes Solutions

In the evolving realm of COA insights and transformative strategies, COS and FingerPost's symphony of innovation and expertise surges onward, etching a legacy of patient-centric brilliance onto the canvas of clinical outcomes research.